| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.32▲ | 1.35▼ | 1.37▼ | 1.34▼ | 1.38▼ |
| MA10 | 1.35▼ | 1.36▼ | 1.36▼ | 1.37▼ | 1.45▼ |
| MA20 | 1.35▼ | 1.34▼ | 1.33▲ | 1.38▼ | 1.52▼ |
| MA50 | 1.33▼ | 1.36▼ | 1.37▼ | 1.43▼ | 1.89▼ |
| MA100 | 1.37▼ | 1.37▼ | 1.39▼ | 1.60▼ | 3.25▼ |
| MA200 | 1.38▼ | 1.38▼ | 1.40▼ | 1.84▼ | 8.56▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | 0.000▲ | 0.003▲ | -0.002▼ | 0.003▲ |
| RSI | 46.854▼ | 45.891▼ | 44.981▼ | 44.834▼ | 40.622▼ |
| STOCH | 32.500 | 56.325 | 65.166 | 39.879 | 35.690 |
| WILL %R | -70.000 | -70.000 | -60.870 | -68.421 | -73.737 |
| CCI | -66.340 | -69.444 | -42.365 | -130.748▼ | -88.898 |
|
Friday, January 23, 2026 03:03 AM
In Growing Biodefense Preparedness Efforts. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, was featured in a recent article discussing its development of a vacc ...
|
|
Sunday, January 18, 2026 07:14 AM
Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received ...
|
|
Wednesday, December 17, 2025 05:23 AM
Soligenix, Inc. (NASDAQ: SNGX) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis. In this extension (Cohort 3) of the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 29/01/26 | 1.34 | 1.34 | 1.30 | 1.33 | 96,063 |
| 28/01/26 | 1.33 | 1.41 | 1.31 | 1.37 | 133,800 |
| 27/01/26 | 1.30 | 1.38 | 1.28 | 1.34 | 186,200 |
| 26/01/26 | 1.35 | 1.38 | 1.27 | 1.29 | 321,500 |
| 23/01/26 | 1.44 | 1.44 | 1.37 | 1.38 | 113,700 |
| 22/01/26 | 1.43 | 1.46 | 1.40 | 1.42 | 192,600 |
| 21/01/26 | 1.38 | 1.43 | 1.35 | 1.40 | 235,100 |
| 20/01/26 | 1.40 | 1.41 | 1.35 | 1.38 | 146,400 |
| 16/01/26 | 1.43 | 1.43 | 1.34 | 1.41 | 140,414 |
| 15/01/26 | 1.40 | 1.40 | 1.33 | 1.34 | 202,186 |
|
|
||||
|
|
||||
|
|